Cargando…

Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection

BACKGROUND: Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI). It restores the disrupted intestinal microbiota and subsequently suppresses C. difficile. The long-term stability of the intestinal microbiota and the recovery of mucos...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalanka, Jonna, Mattila, Eero, Jouhten, Hanne, Hartman, Jorn, de Vos, Willem M., Arkkila, Perttu, Satokari, Reetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057499/
https://www.ncbi.nlm.nih.gov/pubmed/27724956
http://dx.doi.org/10.1186/s12916-016-0698-z
_version_ 1782459082653827072
author Jalanka, Jonna
Mattila, Eero
Jouhten, Hanne
Hartman, Jorn
de Vos, Willem M.
Arkkila, Perttu
Satokari, Reetta
author_facet Jalanka, Jonna
Mattila, Eero
Jouhten, Hanne
Hartman, Jorn
de Vos, Willem M.
Arkkila, Perttu
Satokari, Reetta
author_sort Jalanka, Jonna
collection PubMed
description BACKGROUND: Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI). It restores the disrupted intestinal microbiota and subsequently suppresses C. difficile. The long-term stability of the intestinal microbiota and the recovery of mucosal microbiota, both of which have not been previously studied, are assessed herein. Further, the specific bacteria behind the treatment efficacy are also investigated. METHODS: We performed a high-throughput microbiota profiling using a phylogenetic microarray analysis of 131 faecal and mucosal samples from 14 rCDI patients pre- and post-FMT during a 1-year follow-up and 23 samples from the three universal donors over the same period. RESULTS: The FMT treatment was successful in all patients. FMT reverted the patients’ bacterial community to become dominated by Clostridium clusters IV and XIVa, the major anaerobic bacterial groups of the healthy gut. In the mucosa, the amount of facultative anaerobes decreased, whereas Bacteroidetes increased. Post-FMT, the patients’ microbiota profiles were more similar to their own donors than what is generally observed for unrelated subjects and this striking similarity was retained throughout the 1-year follow-up. Furthermore, the universal donor approach allowed us to identify bacteria commonly established in all CDI patients and revealed a commonly acquired core microbiota consisting of 24 bacterial taxa. CONCLUSIONS: FMT induces profound microbiota changes, therefore explaining the high clinical efficacy for rCDI. The identification of commonly acquired bacteria could lead to effective bacteriotherapeutic formulations. FMT can affect microbiota in the long-term and offers a means to modify it relatively permanently for the treatment of microbiota-associated diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0698-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5057499
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50574992016-10-24 Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection Jalanka, Jonna Mattila, Eero Jouhten, Hanne Hartman, Jorn de Vos, Willem M. Arkkila, Perttu Satokari, Reetta BMC Med Research Article BACKGROUND: Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection (rCDI). It restores the disrupted intestinal microbiota and subsequently suppresses C. difficile. The long-term stability of the intestinal microbiota and the recovery of mucosal microbiota, both of which have not been previously studied, are assessed herein. Further, the specific bacteria behind the treatment efficacy are also investigated. METHODS: We performed a high-throughput microbiota profiling using a phylogenetic microarray analysis of 131 faecal and mucosal samples from 14 rCDI patients pre- and post-FMT during a 1-year follow-up and 23 samples from the three universal donors over the same period. RESULTS: The FMT treatment was successful in all patients. FMT reverted the patients’ bacterial community to become dominated by Clostridium clusters IV and XIVa, the major anaerobic bacterial groups of the healthy gut. In the mucosa, the amount of facultative anaerobes decreased, whereas Bacteroidetes increased. Post-FMT, the patients’ microbiota profiles were more similar to their own donors than what is generally observed for unrelated subjects and this striking similarity was retained throughout the 1-year follow-up. Furthermore, the universal donor approach allowed us to identify bacteria commonly established in all CDI patients and revealed a commonly acquired core microbiota consisting of 24 bacterial taxa. CONCLUSIONS: FMT induces profound microbiota changes, therefore explaining the high clinical efficacy for rCDI. The identification of commonly acquired bacteria could lead to effective bacteriotherapeutic formulations. FMT can affect microbiota in the long-term and offers a means to modify it relatively permanently for the treatment of microbiota-associated diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0698-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-11 /pmc/articles/PMC5057499/ /pubmed/27724956 http://dx.doi.org/10.1186/s12916-016-0698-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jalanka, Jonna
Mattila, Eero
Jouhten, Hanne
Hartman, Jorn
de Vos, Willem M.
Arkkila, Perttu
Satokari, Reetta
Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection
title Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection
title_full Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection
title_fullStr Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection
title_full_unstemmed Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection
title_short Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection
title_sort long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent clostridium difficile infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057499/
https://www.ncbi.nlm.nih.gov/pubmed/27724956
http://dx.doi.org/10.1186/s12916-016-0698-z
work_keys_str_mv AT jalankajonna longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection
AT mattilaeero longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection
AT jouhtenhanne longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection
AT hartmanjorn longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection
AT devoswillemm longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection
AT arkkilaperttu longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection
AT satokarireetta longtermeffectsonluminalandmucosalmicrobiotaandcommonlyacquiredtaxainfaecalmicrobiotatransplantationforrecurrentclostridiumdifficileinfection